

# Shon Lewis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8072423/publications.pdf>

Version: 2024-02-01

114  
papers

9,222  
citations

53794

45  
h-index

40979

93  
g-index

124  
all docs

124  
docs citations

124  
times ranked

8329  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cognitive function in early-phase schizophrenia-spectrum disorder: IQ subtypes, brain volume and immune markers. <i>Psychological Medicine</i> , 2022, , 1-10.	4.5	3
2	The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia. <i>Lancet Psychiatry</i> , 2022, 9, 477-486.	7.4	13
3	Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. <i>Health Technology Assessment</i> , 2022, 26, 1-174.	2.8	16
4	Digital screening for postnatal depression: mixed methods proof-of-concept study. <i>BMC Pregnancy and Childbirth</i> , 2022, 22, .	2.4	2
5	Acceptability of reducing sedentariness using a mobile-phone application based on "if then" plans for people with psychosis: A focus-group study conducted in North West England, UK. <i>International Journal of Social Psychiatry</i> , 2022, 68, 1100-1107.	3.1	2
6	Impaired verbal memory function is related to anterior cingulate glutamate levels in schizophrenia: findings from the STRATA study. , 2022, 8, .		1
7	Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment. <i>Brain, Behavior, and Immunity</i> , 2021, 91, 498-504.	4.1	28
8	Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 444-455.	4.3	9
9	Adaptive Symptom Monitoring Using Hidden Markov Models " An Application in Ecological Momentary Assessment. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2021, 25, 1770-1780.	6.3	8
10	Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA). <i>Schizophrenia Bulletin</i> , 2021, 47, 505-516.	4.3	51
11	Peripheral immune markers and antipsychotic non-response in psychosis. <i>Schizophrenia Research</i> , 2021, 230, 1-8.	2.0	29
12	Digital mental health in China: a systematic review. <i>Psychological Medicine</i> , 2021, 51, 2552-2570.	4.5	28
13	Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study. <i>BMJ Open</i> , 2021, 11, e054160.	1.9	2
14	Co-designing new tools for collecting, analysing and presenting patient experience data in NHS services: working in partnership with patients and carers. <i>Research Involvement and Engagement</i> , 2021, 7, 85.	2.9	5
15	Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2020, 34, 3-78.	4.0	259
16	A longitudinal comparison of two neurocognitive test batteries in patients with schizophrenia and healthy volunteers: Time effects on neuropsychological performance and their relation to functional outcome. <i>Schizophrenia Research</i> , 2020, 216, 347-356.	2.0	6
17	Early Signs Monitoring to Prevent Relapse in Psychosis and Promote Well-Being, Engagement, and Recovery: Protocol for a Feasibility Cluster Randomized Controlled Trial Harnessing Mobile Phone Technology Blended With Peer Support. <i>JMIR Research Protocols</i> , 2020, 9, e15058.	1.0	24
18	Smartphone-Enhanced Symptom Management In Psychosis: Open, Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2020, 22, e17019.	4.3	25

#	ARTICLE	IF	CITATIONS
19	Developing a Theory-Informed Smartphone App for Early Psychosis: Learning Points From a Multidisciplinary Collaboration. <i>Frontiers in Psychiatry</i> , 2020, 11, 602861.	2.6	12
20	Digital methods to enhance the usefulness of patient experience data in services for long-term conditions: the DEPEND mixed-methods study. <i>Health Services and Delivery Research</i> , 2020, 8, 1-128.	1.4	3
21	Cluster Hidden Markov Models: An Application to Ecological Momentary Assessment of Schizophrenia. , 2019, , .		1
22	Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate. <i>NPJ Schizophrenia</i> , 2019, 5, 12.	3.6	28
23	“They Are Not Hard-to-Reach Clients. We Have Just Got Hard-to-Reach Services.” Staff Views of Digital Health Tools in Specialist Mental Health Services.. <i>Frontiers in Psychiatry</i> , 2019, 10, 344.	2.6	64
24	Stress and cognitive biases in schizotypy: A two-site study of bias against disconfirmatory evidence and jumping to conclusions. <i>European Psychiatry</i> , 2019, 62, 20-27.	0.2	7
25	Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. <i>Translational Psychiatry</i> , 2019, 9, 20.	4.8	52
26	Digital biomarkers from geolocation data in bipolar disorder and schizophrenia: a systematic review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019, 26, 1412-1420.	4.4	45
27	Blending active and passive digital technology methods to improve symptom monitoring in early psychosis. <i>Microbial Biotechnology</i> , 2019, 13, 1271-1275.	1.7	27
28	Towards a consensus around standards for smartphone apps and digital mental health. <i>World Psychiatry</i> , 2019, 18, 97-98.	10.4	237
29	Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT. <i>Efficacy and Mechanism Evaluation</i> , 2019, 6, 1-66.	0.7	2
30	A Theory-Informed Digital Health Intervention in People with Severe Mental Health Problems. <i>Studies in Health Technology and Informatics</i> , 2019, 264, 526-530.	0.3	8
31	Actissist: Proof-of-Concept Trial of a Theory-Driven Digital Intervention for Psychosis. <i>Schizophrenia Bulletin</i> , 2018, 44, 1070-1080.	4.3	160
32	The COMMAND trial of cognitive therapy to prevent harmful compliance with command hallucinations: predictors of outcome and mediators of change. <i>Psychological Medicine</i> , 2018, 48, 1966-1974.	4.5	23
33	The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial. <i>Lancet Psychiatry</i> , the, 2018, 5, 885-894.	7.4	133
34	The COMMAND trial of cognitive therapy for harmful compliance with command hallucinations (CTCH): a qualitative study of acceptability and tolerability in the UK. <i>BMJ Open</i> , 2018, 8, e021657.	1.9	8
35	Digital interventions in severe mental health problems: lessons from the Actissist development and trial. <i>World Psychiatry</i> , 2018, 17, 230-231.	10.4	21
36	Early Psychosis Service User Views on Digital Technology: Qualitative Analysis. <i>JMIR Mental Health</i> , 2018, 5, e10091.	3.3	57

#	ARTICLE	IF	CITATIONS
37	Culturally-adapted Family Intervention (CaFI) for African-Caribbeans diagnosed with schizophrenia and their families: a feasibility study protocol of implementation and acceptability. Pilot and Feasibility Studies, 2016, 2, 39.	1.2	27
38	Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial. Health Technology Assessment, 2016, 20, 1-46.	2.8	25
39	Using mobile technology to deliver a cognitive behaviour therapy-informed intervention in early psychosis (Actissist): study protocol for a randomised controlled trial. Trials, 2015, 16, 404.	1.6	38
40	Technological innovations in mental healthcare: harnessing the digital revolution. British Journal of Psychiatry, 2015, 206, 263-265.	2.8	272
41	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for its Methodology and a Review of the Effectiveness of Switching Antipsychotics. Schizophrenia Bulletin, 2015, 41, 549-558.	4.3	47
42	The Promise of Biological Markers for Treatment Response in First-Episode Psychosis: A Systematic Review. Schizophrenia Bulletin, 2015, 41, 559-573.	4.3	93
43	Calibration and cross-validation of MCCB and CogState in schizophrenia. Psychopharmacology, 2015, 232, 3873-3882.	3.1	31
44	Stratified medicine for mental disorders. European Neuropsychopharmacology, 2014, 24, 5-50.	0.7	152
45	Cognitive behaviour therapy to prevent harmful compliance with command hallucinations (COMMAND): a randomised controlled trial. Lancet Psychiatry, the, 2014, 1, 23-33.	7.4	120
46	Mood variability predicts the course of suicidal ideation in individuals with first and second episode psychosis. Psychiatry Research, 2013, 206, 240-245.	3.3	16
47	Psychotic Experiences and Psychotic Disorders at Age 18 in Relation to Psychotic Experiences at Age 12 in a Longitudinal Population-Based Cohort Study. American Journal of Psychiatry, 2013, 170, 742-750.	7.2	273
48	Pathways to Violent Behavior During First-Episode Psychosis. JAMA Psychiatry, 2013, 70, 1287.	11.0	99
49	Reducing duration of untreated psychosis: care pathways to early intervention in psychosis services. British Journal of Psychiatry, 2013, 203, 58-64.	2.8	135
50	A Comparison of Two Delivery Modalities of a Mobile Phone-Based Assessment for Serious Mental Illness: Native Smartphone Application vs Text-Messaging Only Implementations. Journal of Medical Internet Research, 2013, 15, e60.	4.3	128
51	A treatment approach to the patient with first-episode schizophrenia. , 2012, , 237-251.		0
52	A treatment approach to the patient with first-episode schizophrenia. , 2012, , 237-251.		0
53	Auditory false perceptions are mediated by psychosis risk factors. Cognitive Neuropsychiatry, 2011, 16, 289-302.	1.3	36
54	The negative and positive self: a longitudinal study examining self-esteem, paranoia and negative symptoms in individuals with first-episode psychosis. Microbial Biotechnology, 2011, 5, 150-155.	1.7	33

#	ARTICLE	IF	CITATIONS
55	A multi-centre, randomised controlled trial of cognitive therapy to prevent harmful compliance with command hallucinations. <i>BMC Psychiatry</i> , 2011, 11, 155.	2.6	18
56	Distress and Metacognition in Psychosis Prone Individuals. <i>Journal of Nervous and Mental Disease</i> , 2010, 198, 99-104.	1.0	30
57	Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2010, 341, c6325-c6325.	2.3	187
58	Prediction of Psychosis in Adolescents and Young Adults at High Risk. <i>Archives of General Psychiatry</i> , 2010, 67, 241.	12.3	575
59	Duration of untreated psychosis. , 2009, , 125-146.		3
60	Second-generation antipsychotics: a therapeutic downturn?. <i>Psychological Medicine</i> , 2009, 39, 1603.	4.5	3
61	Evaluating integrated MI and CBT for people with psychosis and substance misuse: Recruitment, retention and sample characteristics of the MIDAS trial. <i>Addictive Behaviors</i> , 2009, 34, 859-866.	3.0	42
62	Assessing illicit substance use in schizophrenia: The relationship between self report and detection by hair analysis. <i>Schizophrenia Research</i> , 2009, 114, 180-181.	2.0	7
63	A Randomized Controlled Trial of the Cost-Utility of Second-Generation Antipsychotics in People with Psychosis and Eligible for Clozapine. <i>Value in Health</i> , 2008, 11, 549-562.	0.3	27
64	CATIE and CUTLASS: can we handle the truth?. <i>British Journal of Psychiatry</i> , 2008, 192, 161-163.	2.8	130
65	Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. <i>British Journal of Psychiatry</i> , 2007, 191, 14-22.	2.8	97
66	Hallucination proneness, schizotypy and meta-cognition. <i>Behaviour Research and Therapy</i> , 2007, 45, 1401-1408.	3.1	29
67	Cognitive and neural processes in non-clinical auditory hallucinations. <i>British Journal of Psychiatry</i> , 2007, 191, s76-s81.	2.8	92
68	The Psychotic Symptom Rating Scales (PSYRATS): Their usefulness and properties in first episode psychosis. <i>Schizophrenia Research</i> , 2007, 89, 119-122.	2.0	136
69	Prospects for a cognitive-developmental account of psychotic experiences. <i>British Journal of Clinical Psychology</i> , 2007, 46, 155-173.	3.5	72
70	First- vs Second-Generation Antipsychotic Drugs in Schizophreniaâ€”Reply. <i>Archives of General Psychiatry</i> , 2007, 64, 979.	12.3	6
71	Suicide behaviour over 18 months in recent onset schizophrenic patients: The effects of CBT. <i>Schizophrenia Research</i> , 2006, 83, 15-27.	2.0	80
72	Influence of age on outcome of psychological treatments in first-episode psychosis. <i>British Journal of Psychiatry</i> , 2006, 188, 250-254.	2.8	55

#	ARTICLE	IF	CITATIONS
73	Identification of young people at risk of psychosis. <i>Advances in Psychiatric Treatment</i> , 2006, 12, 249-255.	0.5	10
74	Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients. <i>Archives of General Psychiatry</i> , 2005, 62, 975.	12.3	1,303
75	Attitudes to atypical and conventional antipsychotic drug treatment in clinicians participating in the cutlass study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2005, 9, 35-40.	2.4	6
76	Psychological Interventions in Early Psychosis. <i>Schizophrenia Bulletin</i> , 2005, 31, 697-704.	4.3	49
77	The Presence of Neurological Soft Signs Along the Psychosis Proneness Continuum. <i>Schizophrenia Bulletin</i> , 2005, 32, 573-577.	4.3	60
78	Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. <i>Schizophrenia Research</i> , 2005, 75, 135-137.	2.0	112
79	Essential elements of an early intervention service for psychosis: the opinions of expert clinicians. <i>BMC Psychiatry</i> , 2004, 4, 17.	2.6	64
80	Cognitive-behavioural therapy in first-episode and early schizophrenia. <i>British Journal of Psychiatry</i> , 2004, 184, 231-239.	2.8	243
81	Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort. <i>Schizophrenia Research</i> , 2003, 65, 75-86.	2.0	181
82	The evolution of symptoms in the early course of non-affective psychosis. <i>Schizophrenia Research</i> , 2003, 63, 171-179.	2.0	45
83	Is treatment research in people at high risk of psychosis ethical?. <i>Journal of Mental Health</i> , 2003, 12, 359-362.	1.9	1
84	Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. <i>British Journal of Psychiatry</i> , 2003, 183, 418-426.	2.8	204
85	Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: Acute-phase outcomes. <i>British Journal of Psychiatry</i> , 2002, 181, s91-s97.	2.8	311
86	Postcode prescribing in psychiatry. <i>Psychiatric Bulletin</i> , 2000, 24, 420-422.	0.3	14
87	Cognitive Behavioral Intervention for Individuals with Severe Mental Illness Who Have a Substance Misuse Problem. <i>Psychiatric Rehabilitation Skills</i> , 2000, 4, 216-233.	0.1	16
88	Lack of normal pattern of cerebral asymmetry in familial schizophrenic patients and their relatives - The Maudsley Family Study. <i>Schizophrenia Research</i> , 1999, 40, 111-120.	2.0	82
89	Duration of treatment in schizophrenia. <i>Journal of Forensic Psychiatry Psychology</i> , 1999, 10, 491-496.	0.3	0
90	Randomised controlled effectiveness trial of a needs-based psychosocial intervention service for carers of people with schizophrenia. <i>British Journal of Psychiatry</i> , 1999, 174, 505-511.	2.8	126

#	ARTICLE	IF	CITATIONS
91	Brain changes in schizophrenia. <i>British Journal of Psychiatry</i> , 1998, 173, 132-138.	2.8	102
92	Research and development in the NHS. <i>British Journal of Psychiatry</i> , 1998, 172, 194-196.	2.8	0
93	Which atypical antipsychotic?. <i>British Journal of Psychiatry</i> , 1998, 172, 106-109.	2.8	49
94	Individual cognitive-behavioural interventions in early psychosis. <i>British Journal of Psychiatry</i> , 1998, 172, 101-106.	2.8	46
95	The Maudsley family study I: Structural brain changes on magnetic resonance imaging in familial schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1997, 21, 1297-1315.	4.8	20
96	Doctor-patient interactions in oncology. <i>Social Science and Medicine</i> , 1996, 42, 1511-1519.	3.8	347
97	No news is not good news: Information preferences of patients with cancer. <i>Psycho-Oncology</i> , 1995, 4, 197-202.	2.3	216
98	Increased Intracerebral Cerebrospinal Fluid Spaces Predict Unemployment and Negative Symptoms in Psychotic Illness a Prospective Study. <i>British Journal of Psychiatry</i> , 1995, 166, 750-758.	2.8	41
99	Correlates of left-handedness in a large sample of schizophrenic patients. <i>Schizophrenia Research</i> , 1995, 18, 37-41.	2.0	27
100	ICD-10: A Neuropsychiatrist's Nightmare?. <i>British Journal of Psychiatry</i> , 1994, 164, 157-158.	2.8	11
101	Age at Onset, Sex, and Familial Psychiatric Morbidity in Schizophrenia. <i>British Journal of Psychiatry</i> , 1994, 165, 466-473.	2.8	151
102	Information preferences of patients with cancer. <i>Lancet, The</i> , 1994, 344, 1576.	13.7	61
103	Cannabis and acute psychosis. <i>Schizophrenia Research</i> , 1994, 13, 161-167.	2.0	96
104	Low Birth Weight and Schizophrenia. <i>British Journal of Psychiatry</i> , 1994, 165, 357-362.	2.8	109
105	Life Events and Psychosis. <i>British Journal of Psychiatry</i> , 1993, 162, 72-79.	2.8	255
106	Sex differences in the familial risk of schizophrenia: data from RÅ¼din's study. <i>British Journal of Psychiatry</i> , 1992, 161, 131-132.	2.8	2
107	Sex and Schizophrenia: Vive la DiffÅ©rence. <i>British Journal of Psychiatry</i> , 1992, 161, 445-450.	2.8	95
108	Pre-morbid Adjustment and Personality in Psychosis. <i>British Journal of Psychiatry</i> , 1991, 158, 171-176.	2.8	193

#	ARTICLE	IF	CITATIONS
109	The right stuff? a prospective controlled trial of trainees' research. <i>Psychiatric Bulletin</i> , 1991, 15, 478-480.	0.3	15
110	Delusional Misidentification, AIDS and the Right Hemisphere. <i>British Journal of Psychiatry</i> , 1990, 157, 608-610.	2.8	33
111	The Heredity of Behavior Disorders in Adults and Children By S. G. Vandenburg, S. M. Singer and D. L. Pauls New York: Plenum. 1986. Pp 301. \$35.00.. <i>British Journal of Psychiatry</i> , 1987, 151, 277-277.	2.8	0
112	Transient Psychosis: Diagnosis, Management and Evaluation. Edited by Joe. P. Tupin, Uriel Halbreich and Jesus J. Pena. New York: Brunner/Mazel. 1984. Pp. 307. \$30.00.. <i>British Journal of Psychiatry</i> , 1985, 146, 226-226.	2.8	0
113	Falling Incidence of Schizophrenia?. <i>British Journal of Psychiatry</i> , 1985, 146, 560-561.	2.8	3
114	Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with First Episode Psychosis: the OPTiMiSE cohort study. <i>Schizophrenia Bulletin Open</i> , 0, , .	1.7	2